Seal Rock Therapeutics Email Format

Biotechnology ResearchUnited States11-50 Employees

Seal Rock Therapeutics is a clinical-stage company developing novel therapeutics for diseases of high unmet need. Seal Rock’s pioneering LRRK2/ASK1 signaling complex (LASC) inhibitors are disease modifying agents for Parkinson's disease and ALS by blocking multiple causal pathways and severing feedback loops that cause neurodegeneration and neuroinflammation.  Several are now in preclinical development.  The ASK1 inhibitor SRT-015 has shown excellent safety and efficacy in a phase 1 trial.  We are developing oral SRT-015 for cirrhosis and rare liver diseases, and our partner Genfit is developing it for acute-on-chronic liver failure.condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis.  Additional opportunities with ASK1 inhibitors include cardiac, immunological and neurodegenerative indications.

Sign up for free to view info

Company overview Employee directory